

# Index

- 2 × 2 factorial design 83–8, 141–2
- accelerated failure time (AFT) 101, 102–3, 107–12
- access to care 245–6
- ACT *see* anti-malarial combination trial
- acute leukaemia 178–9
- acute rejection of transplants 157
- advanced carcinoma of the cervix *see* cervical cancer
- AFT *see* accelerated failure time
- AHSD *see* arteriosclerotic heart disease
- AIC *see* Akaike's information criteria
- AIDS *see* HIV/AIDS
- Akaike's information criteria (AIC) 114–15
- amenorrhoea 61
- angina pectoris 241–2
- anti-malarial combination trial (ACT) 247–9
- aplastic anaemia 178–9
- arteriosclerotic heart disease (ASHD) 167–8
- aspirin 87–8, 142
- asthma 140
- astrocytoma 200
- atenolol 241–2
- automated searches 172–3
- azathioprine 231–2
- azoospermic males 6
  
- bivariable screens 172
- bleeding irregularities 61
- bodyweight 81–2
- bone marrow 65, 178–9
- Bournemouth score groupings 79
- brain cancer
  - Cox model 126–9, 131–5, 142–3, 145–7, 151, 158–66
  - non-proportional hazards 224–5
  - prognostic indices 190–1, 194, 199–205
- breast cancer 136–7, 184, 190
- Breslow tests 226–7
- burns 11–20
- busulphan 5
  
- candidate variables 189–90
- carcinoma of the cervix *see* cervical cancer
  
- case-control studies 14
- categorical variables 135–8, 166, 169
- CD4 count 37–8
- censored survival times 2, 3, 24–5, 35, 88
  - Cox model 151–3
  - parametric modelling 96–8, 115
- cerebrovascular accident (CVA) 167–8
- cervical cancer
  - confidence intervals 10, 66–8
  - hazard ratio 62, 66–8
  - Logrank test 52–9, 68–82, 228–9
  - Mantel-Haenszel test 68–9
  - non-proportional hazards 228–9
  - parametric modelling 99–102, 108, 112
- CGL *see* chronic granulocytic leukaemia
- change-in-estimates 156, 165–6
- chemotherapy 5, 123
- chi-squared test 18–19
  - Cox model 127, 136, 162–4
  - factorial design 88
  - homogeneity between groups 76, 79–80
  - non-proportional hazards 228–9
  - stratified Logrank test 71
- chronic granulocytic leukaemia (CGL) 4–5
- chronic heart failure 52
- chronic obstructive pulmonary disease (COPD) 167–8
- CIM *see* cumulative incidence method
- clinical significance 17–18
- clinically important difference 211
- clustered data 182, 245–9
- colon cancer 215–17
- colonisation-free rates 210
- colorectal cancer
  - Cox model 169
  - parametric modelling 92–8, 105–7
  - survival curves 26–7, 29–33, 37, 39, 40–4, 46–7
- combination treatments 83–8, 123, 241–2, 243–4
- competing risks 236–40
- complementary log plots 94–8, 121–4, 146–7, 224
- computing packages 21

- conditional probabilities 29–30
- confidence intervals (CI) 10–12, 17, 22
  - Cox model 127–8, 155
  - Greenwood's method 41–2
  - hazard ratio 65–7
  - median survival times 44–5
  - parametric modelling 98, 100, 107–8
  - Peto's method 42
  - survival curves 40–5, 65–7
  - transformation method 43
- confirmatory trials 211
- confounders 155–6, 157–8, 165, 172
- constant hazard rate 91–8
- continuous data 1–2
- continuous time-varying covariates 178–9
- continuous variables 166–7
- contraceptives 45, 60–1, 81–2, 236–40
- COPD *see* chronic obstructive pulmonary disease
- coronary artery disease 142
- Cox model 121–53, 155–73, 175–86
  - all possible combinations 164–5
  - assessing proportionality 146–9
  - automated searches 172–3
  - binary variable 176–7
  - bivariable screens 172
  - categorical variables 135–8
  - change-in-estimates 156, 165–6
  - clustered data 182
  - comparing groups 125–8
  - complementary log-plots 121–4, 146–7
  - continuous time-varying covariates 178–9
  - delayed entry 176, 183–4, 185–6
  - discrete time intervals 179–81
  - efficiency 158
  - extensions 175–86
  - factorial design 141–2
  - fixed and time-varying covariates 177
  - forced-entry 156–8
  - interaction model 141–4, 151
  - interactions 169–70
  - likelihood ratio 150–1, 162
  - Logrank test 128, 144–6
  - missing values 170–1
  - more than two explanatory variables 134–5
  - multivariable analysis 155–6
  - multivariable models 139
  - nested models 161
  - non-proportional hazards 179–82
  - paired observations 242–4
  - parametric models 139–40
  - partial likelihood 151–3, 184–6
  - practicalities 170–3
  - prognostic indices 155
  - proportional hazards 124–5, 139–40, 146–9, 159
  - regression models 128–38
  - Schoenfeld residuals 148–9
  - significance levels 171–2
  - significance testing 156, 158–65
  - single explanatory variable 128–32
  - smooth time-varying hazard ratios 181
  - step-down selection 163–4
  - step-up selection 161–3
  - stepwise selection 165–6
  - stratified analysis 144–6, 181–2
  - technical details 151–3, 184–6
  - tied data 153
  - time-dependent 176–81
  - time-scales 182–3
  - truncation 176, 185–6
  - two explanatory variables 132–4
  - updated covariates 184–5
  - variable selection 155–73
  - variable types 155–6, 157–8, 165, 166–70
  - Wald test 127, 150
  - Weibull model 140
    - see also* prognostic indices
- Cox-Snell residuals 115–17
- crossover trials 240–3
- cumulative hazard 87–8, 95
- cumulative incidence method (CIM) 239–40
- cumulative rates 6, 34–5, 60–1, 237–9
- cure models 38, 232–6
- cut-point 138
- CVA *see* cerebrovascular accident
- cystic fibrosis 210, 211, 214
- daily hazard 47–8
- database packages 21
- delayed entry 7–8, 176, 183–4, 185–6
- design variables 156, 157
- diabetes mellitus 167–8, 170
- diagnostics 115–17
- discontinuation 60–1, 237–9
- discrete time intervals 179–81
- distribution
  - exponential 91–103, 105–7, 112, 113–19
  - generalised Gamma 110–12, 113–14
  - log-Logistic 112, 113–14
  - log-Normal 108–10, 113–14
  - Normal 9–10
  - survival curves 48–9
  - Weibull 93, 95, 103–8, 112, 113–19, 140
- Dukes' A/B/C *see* colorectal cancer
- dummy variables 135, 167–8
- ECMV *see* etoposide, cyclophosphamide, methotrexate and vincristine
- effect size 208–10
- efficiency 158

- end-stage renal disease 167–8  
 endpoint 189  
 epidemiology 12–13  
 etoposide, cyclophosphamide, methotrexate and vincristine (ECMV) 123  
 Ewing's sarcoma 187, 235–6  
 exploratory variables 156  
 exponential distribution 91–103, 105–7, 112, 113–19  
 exponential survival curves 208–9
- factorial design 83–8, 141–2  
 fertility 60–1, 81–2, 139  
 fits 133–5, 142–3, 145–7, 159–66, 175, 224–5  
 fixed covariates 175, 177  
 fixed-time points 28, 40, 41–2  
 fluorouracil 141–2  
 follow-up  
   discontinuation 237–9  
   maturity 38–40, 88–90  
   sample sizes 215–16  
 forced-entry 156–8
- gag (p24) antibodies 59–60  
 gaps in exposure time 7–8  
 Gehan tests 226–7  
 generalised Gamma distribution 110–12, 113–14  
 generalised Wilcoxon tests 226–7  
 glyceryl trinitrate 37  
 gold therapy 33–4  
 gossypol 6, 139  
 graft versus host disease (GVHD) 178–9  
 granulocyte counts 178–9  
 Greenwood's method 41–2  
 GVHD *see* graft versus host disease
- hazard rate  
   constant 91–8  
   cumulative hazard 95  
   estimation 93–4  
   parametric modelling 91–102  
   proportional 124–5  
   survival curves 45–9  
   variable 103–4, 115, 124  
   verification 94–8  
   *see also* Cox model  
 hazard ratio (HR) 12–15  
   median survival times 67–8  
   paired observations 243  
   parametric modelling 99–102  
   sample sizes 207–8  
   smooth time-varying 181  
   survival curves 62–9  
 HCC *see* hepatocellular carcinoma  
 heart transplantation 2–3, 24–6, 176–7, 184–5
- heparin 87–8, 142  
 hepatocellular carcinoma (HCC) 23–4, 26, 197–8, 201, 218–20  
 history of fits 133–5, 142–3, 145–7, 159–66, 175, 224–5  
 HIV/AIDS 36–8, 44, 59–60  
 Hodgkin's lymphoma 233–4  
 homogeneity between groups 76, 79  
 HR *see* hazard ratio
- incontinence 225–7  
 influential variables 156  
 infusion times 37  
 initial events 7  
 injectable contraceptives 60–1  
 inoperable hepatocellular carcinoma 197–8, 201, 218–20  
 intention-to-treat (ITT) 7  
 interactions  
   Cox model 141–4, 151, 169–70  
   factorial design 86–8  
 intrauterine devices (IUDs) 45, 237–40  
 ITT *see* intention-to-treat  
 IUDs *see* intrauterine devices
- Kaplan-Meier estimates 2, 4, 21  
   Censor estimate 237, 238–40  
   Cox model 133  
   cure models 234  
   follow-up maturity 39  
   non-proportional hazards 226  
   parametric modelling 96, 106  
   prognostic indices 194, 196, 198  
   survival curves 28–32, 36–41, 51–4, 60, 74–5, 84, 89  
 knowingly influential variables 156
- levamisole 215–17  
 life-table estimates 4–5  
 likelihood ratio (LR) 19–20, 112, 113–14, 150–1, 162  
 linearity 79–82, 169, 217–18  
 log-Logistic distribution 112, 113–14  
 log-Normal distribution 108–10, 113–14  
 Logrank test 12, 21  
   Cox model 128, 144–6  
   stratified 70–4, 85–6, 144–6  
   survival curves 51–61, 63–4, 69, 74–9  
   weighted 228–9  
 LR *see* likelihood ratio  
 lumpectomies 136  
 lung cancer 90, 122–4
- malaria 247–9  
 Mantel-Cox test *see* Logrank test  
 Mantel-Haenszel test 68–9, 226–7, 228

- marital status 148–9, 158, 177  
 mature data 38–40, 88–90  
 maximum likelihood estimate (MLE) 101, 105, 110, 118–19  
 median survival 8–9, 35–7, 39, 44–5, 67–8  
 mesothelioma 13–14  
 meta-analysis 229–32  
 metastatic disease 122–4, 137, 187, 235–6  
 MI *see* myocardial infarction  
 milrinone 52  
 misonidazole 126–9, 133–5, 147, 190–1  
 missing values 170–1  
 mixture models 233–4, 236  
 MLE *see* maximum likelihood estimate  
 mock-ultrasound 63  
 model based comparison 100–2, 106–7  
 motor development 110  
 multiple endpoints 221  
 multiple groups 74–82  
 multiple recurrences 111–17  
 multiple sclerosis 231–2  
 multivariable analysis 139, 155–6, 191–2  
 myelodysplastic syndromes 65, 79  
 myocardial infarction (MI) 87–8, 142
- nasopharyngeal carcinoma 110–17  
 negative failure times 8  
 neonates 47, 110, 179–81, 207  
 nested models 113, 161  
 NHL *see* non-Hodgkin's lymphoma  
 nifedipine 241–2  
 node-positive breast cancer 190  
 non-Hodgkin's lymphoma (NHL) 196–7  
 non-linear trend 82  
 non-mixture models 234–6  
 non-nested models 114–15  
 non-observed events *see* censored survival times  
 non-proportional hazards 223–9  
   Cox model 179–82  
   Gehan tests 226–7  
   Peto-Prentice tests 227–9  
   Tarone-Ware tests 227  
   weighted Mantel-Haenszel tests 226–7, 228  
 non-scaled residuals 148  
 non-small cell lung cancer (NSCLC) 90, 122–4, 219  
 Normal distributions 9–10  
 NSCLC *see* non-small cell lung cancer
- observed separation (OSEP) 198–201, 205  
 odds ratio (OR) 13–15  
 one-sided tests 212  
 optimal cut-point 138  
 OR *see* odds ratio  
 OSEP *see* observed separation  
 ovarian cancer 230
- p*-values 16–17, 155, 163–4  
 pain relief 67, 83  
 paired observations 240–9  
   analysis of correlated data 244–9  
   clustered data 245–7  
   Cox model 242–4, 246  
   crossover trials 240–2, 243–4  
   recurrent events 247–9  
 parametric modelling 91–119  
   accelerated failure time 101, 102–3, 107–12  
   comparing models 112–15  
   complementary log plots 94–8  
   confidence intervals 98, 100, 107–8  
   constant hazard rate 91–8  
   Cox model 139–40  
   Cox-Snell residuals 115–17  
   cumulative hazard 95  
   diagnostics 115–17  
   exponential distribution 91–103, 105–7, 112–19  
   generalised Gamma distribution 110–12, 113–14  
   Kaplan-Meier estimates 96, 106  
   likelihood ratio test 112, 113–14  
   log-Logistic distribution 112, 113–14  
   log-Normal distribution 108–10, 113–14  
   maximum likelihood estimate 101, 105, 110, 118–19  
   modelling strategies 117–18  
   nested models 113  
   non-nested models 114–15  
   proportional hazards 99, 101–3, 107–9  
   sample sizes 220  
   survival curve comparisons 99–102, 106–7  
   technical details 118–19  
   variable hazard rate 103–4  
   Weibull distribution 93, 95, 103–8, 112, 113–19  
 parsimonious models 155  
 partial likelihood (PL) 151–3, 184–6  
 pelvic inflammatory disease (PID) 45  
 Peto-Prentice tests 227–9  
 Peto's method 42  
 PH *see* proportional hazards  
 PI *see* prognostic indices  
 PID *see* pelvic inflammatory disease  
 PL *see* partial likelihood  
 Ponderal Index 179–81  
 power, sample sizes 212–13  
 predicted separation (PSEP) 198–201, 205  
 pregnancy rates 81–2  
 Prentice, Williams and Peterson (PWP) model 247–9  
 pressure sores 63  
 product-limit estimator *see* Kaplan-Meier estimates

- prognosis 129, 131–2, 136–8, 175  
prognostic indices (PI) 187–206  
  candidate subjects 188–9  
  candidate variables 189–90  
  Cox model 155  
  devising a new index 192–9  
  endpoint 189  
  established indices 205–6  
  fitting the model 192  
  modification 205  
  multivariable models 191–2  
  predicted prognostic information 198–9  
  scoring the patients 192–4  
  selecting the model 190–2  
  simplifying the model 194–8  
  testing 199–202  
  training data 188, 198–9  
  univariate models 190  
  updating the index 202–5  
  validation data 188–9, 198–9  
  validation sets 199–200  
  verification 205  
progression 37–8, 59–60  
proportional hazards (PH) 99, 101–3, 107–9  
  *see also* Cox model  
PSEP *see* predicted separation  
*Pseudomonas aeruginosa* 210  
PWP *see* Prentice, Williams and Peterson
- quadratic trend 82  
query variables 156
- RA *see* rheumatoid arthritis  
radiosensitisers 52–3, 126–9, 133–5  
radiotherapy 5, 52–3, 89, 122, 126–9, 133–5,  
  141–2, 158–66, 190–1, 199–202  
randomised trials  
  Cox model 157  
  crossover trials 241  
  cumulative incidence 240  
  factorial designs 83–7  
  follow-up 88–9  
  hazard ratio 63–4  
  initial events 7  
  Logrank test 52–9, 71, 74  
  recurrent events 247–9  
  significance tests 17  
  survival curves 23  
recovery rates 6  
recurrent events 110–17, 175, 247–9  
regression comparison 100–2, 106–7  
regression models *see* Cox model  
rejection of transplants 157  
relative risk (RR) 12–13, 14–15  
renal disease 167–8  
renal transplants 157  
replication errors 219  
resectable colon cancer 215–17  
retinal infarctions 40  
retrospective studies 14  
rheumatoid arthritis (RA) 33–4  
robust standard error 245, 246–7  
RR *see* relative risk
- sample sizes 207–21  
  calculations 220–1  
  clinically important difference 211  
  duration of study 216–17  
  effect size 208–10  
  follow-up losses 215–16  
  limited resources 221  
  linear relationships 217–18  
  multiple endpoints 221  
  number of events 213–14  
  number of subjects 214  
  number of variables 218–19  
  one- or two-sided tests 212  
  parametric modelling 220  
  power 212–13  
  practicalities 220–1  
  regression problems 217–20  
  sample size tables 214–15  
  test size 211–12  
  training data 219–20  
  two-group comparative studies 213–17  
  validation data 219–20  
scaled residuals 148–9  
Schoenfeld residuals 148–9  
SCLC *see* small cell lung cancer  
SE *see* standard error  
segment depression 241–2, 243  
severe burns 11–20  
severe pain 67, 83  
significance tests 15–20  
  chi-squared test 18–19  
  clinical/statistical significance 17–18  
  confidence intervals 17  
  Cox model 156, 158–65, 171–2  
  likelihood ratio test 19–20  
  z-test 15–17  
small cell lung cancer (SCLC) 47, 123–4  
smooth time-varying hazard ratios 181  
software packages 21  
sperm function 6  
sperm recovery 139  
stage of disease 70–4  
standard error (SE) 245, 246–7  
statistical computing 21  
statistical significance 17–18  
step-down selection 163–4  
step-up selection 161–3  
sterility 6

- stratified analysis 181–2
- stratified Logrank test 70–4, 85–6, 144–6
- stroke 129–30
- study endpoint 189
- survival curves 23–49, 51–90
  - comparison 51–90, 99–102
  - confidence intervals 40–5, 65–7
  - crossover trials 243–4
  - cumulative healing rates 34–5
  - cure models 234
  - daily hazard 47–8
  - distribution 48–9
  - estimating survival 28–32
  - exponential 208–9
  - factorial designs 83–8
  - fixed-time points 28, 40, 41–2
  - follow-up maturity 38–40, 88–90
  - graphical display 32–5, 99
  - Greenwood's method 41–2
  - hazard rate 45–9
  - hazard ratio 62–9
  - interpretation 37–8
  - Kaplan-Meier estimates 28–32, 36–41, 51–4, 60, 74–5, 86, 90
  - linear trend 79–82
  - Logrank test 51–61, 63–4, 69, 74–9
  - Mantel-Haenszel test 68–9
  - median survival times 35–7, 39, 44–5, 67–8
  - non-linear trend 82
  - non-proportional hazards 226
  - notation 27–8
  - parametric modelling 99–102
  - Peto's method 42
  - prognostic indices 194, 196, 198
  - regression comparison 100–2, 106–7
  - sample sizes 208–9
  - stratified Logrank test 70–4, 85–6
  - survival time data 23–8
  - technical details 48–9
  - tests for trend 79–82
  - three or more groups 74–82
  - transformation method 43
- survival outcomes 156
- survival times
  - censored 2, 3, 24–5, 35, 88, 96–8, 115, 151–3
  - confidence intervals 10–12
  - definitions 1, 6–8
  - delayed entry 7–8
  - distribution 48–9
  - gaps in exposure time 7–8
  - initial events 7
  - median 67–8
  - median survival 8–9
  - Normal distributions 9–10
  - survival curves 23–8
  - zero failure times 8
- tamoxifen 218
- Tarone-Ware tests 227
- TENS *see* transcutaneous electrical nerve stimulus
- test size 211–12
- tests for trend 79–82
- three-dose comparisons 218
- tied data 96–7, 153
- time ratios (TR) 102–3, 110
- time to progression 37–8, 59–60
- time-dependent Cox model 176–81
- TR *see* time ratios
- training data 188, 198–9, 219–20
- transcutaneous electrical nerve stimulus (TENS) 63–4, 83–7
- transformation method 42
- transplants 2–3, 24–6, 157, 176–7, 184–5
- treatment combinations 83–8
- treatment effect homogeneity 232
- trend, test for 79–82
- truncation 176, 185–6
- tumour grade 136, 159–66, 175
- two-group comparative studies 213–17
- two-sided tests 212
- ultrasound 63
- univariate models 190
- unknown variables 156
- unstable coronary artery disease 142
- updated covariates 184–5
- vaginal rings 81–2
- validation data 188–9, 198–200, 202, 219–20
- variable hazard rate 103–4, 115, 124
- VAS *see* visual analogue scale
- VCT *see* voluntary counselling and HIV testing
- venous ulceration 34–5
- visual analogue scale (VAS) 63–4, 83
- voluntary counselling and HIV testing (VCT) 245–6
- Wald test 127, 150
- Weibull distribution 93, 95, 103–8, 112, 113–19, 140
- weighted Logrank tests 228–9
- weighted Mantel-Haenszel tests 226–7, 228
- Wilcoxon tests, generalised 226–7
- z-test 15–17
- zero failure times 8
- Zimbabwe Project on Access to Care and Treatment (ZIMPACT) 245–6



